Peter Bernhardt

TL;DR: Despite the lack of sstr2 at Northern blot analysis in most of the thyroid tumors studied, high T/Bs were in general found when compared with corresponding values for normal thyroid tissue and indicate a possibility of using radiolabeled octreotide for radiation therapy of sStr-positive tumors in the future.

TL;DR: Patients with inferior renal function were exposed to higher renal absorbed dose per administered activity and developed a higher grade of haematological toxicity during 177Lu-DOTATATE treatment, which confirms the tolerability of PRRT in patients with an advanced neuroendocrine tumour but indicates that patients with inferior kidneys are at risk of being exposed toHigher absorbed doses to normal tissue on treatment.

TL;DR: By using the absorbed dose to the kidneys as a limiting factor, treatment with 177Lu-octreotate can be individualized, e.g., overtreatment can be avoided and patients with the potential to receive additional treatment can be identified.

TL;DR: Large interindividual variations in kidney dose were found, demonstrating the need for patient-specific dosimetry and treatment planning and comparing the results obtained with planar imaging and different dosimetric methods.

TL;DR: Human midgut carcinoid xenografts can be cured by receptor-mediated radiation therapy by optimising the uptake of radioligand and taking advantage of the favourable change in biokinetics induced by entrapment of radionuclide in the tumours.